Transmural healing is significantly associated with prevention of clinical relapse in Crohn's disease.

The ACG/CAG 2022 guideline's periendoscopic antithrombotic recommendations are explicitly scoped to EXCLUDE patients at high thromboembolic risk, in whom the guideline states elective procedures should be deferred. Verbatim: 'These recommendations exclude patients at high risk of thromboembolic events in whom elective procedures should be deferred. Such high-risk patients include those within 3 months of acute venous thromboembolism (comprising lower-limb deep vein thrombosis or pulmonary embolism), stroke, or transient ischemic attack; and patients within 3 months of acute coronary syndrome (ACS) event, within 6 months of a drug-eluting stent or 1 month of a bare-metal coronary stent placement without ACS history; or after ACS event within 12 months of a drug-eluting stent placement or 2 months of bare-metal stent placement.' Important qualifier: this appears in narrative/implementation text in the section 'Management of antithrombotic agents in the elective endoscopy setting' as an applicability boundary, it is NOT a numbered, GRADE-rated recommendation, and no certainty-of-evidence rating attaches to the windows. Separately, as a graded statement, Recommendation 14A: 'For patients on dual antiplatelet therapy for secondary cardiovascular prevention who are undergoing elective endoscopic GI procedures, we suggest temporary interruption of the P2Y12 inhibitor while continuing ASA (conditional recommendation, very low certainty of evidence).' Recommendation 18 explicitly reaches no conclusion: the panel 'could not reach a recommendation for or against resuming P2Y12 inhibitor on the same day of the procedure vs 1-7 days after the procedure.'